Cargando…

Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts

BACKGROUND: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. This study aimed to evaluate the prevalence and severity of post COVID-19 condition (PCC) with novel SARS-CoV-2 variants and after prior vaccination. METHODS: We used pooled...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballouz, Tala, Menges, Dominik, Kaufmann, Marco, Amati, Rebecca, Frei, Anja, von Wyl, Viktor, Fehr, Jan S., Albanese, Emiliano, Puhan, Milo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946205/
https://www.ncbi.nlm.nih.gov/pubmed/36812215
http://dx.doi.org/10.1371/journal.pone.0281429
_version_ 1784892282770554880
author Ballouz, Tala
Menges, Dominik
Kaufmann, Marco
Amati, Rebecca
Frei, Anja
von Wyl, Viktor
Fehr, Jan S.
Albanese, Emiliano
Puhan, Milo A.
author_facet Ballouz, Tala
Menges, Dominik
Kaufmann, Marco
Amati, Rebecca
Frei, Anja
von Wyl, Viktor
Fehr, Jan S.
Albanese, Emiliano
Puhan, Milo A.
author_sort Ballouz, Tala
collection PubMed
description BACKGROUND: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. This study aimed to evaluate the prevalence and severity of post COVID-19 condition (PCC) with novel SARS-CoV-2 variants and after prior vaccination. METHODS: We used pooled data from 1350 SARS-CoV-2-infected individuals from two representative population-based cohorts in Switzerland, diagnosed between Aug 5, 2020, and Feb 25, 2022. We descriptively analysed the prevalence and severity of PCC, defined as the presence and frequency of PCC-related symptoms six months after infection, among vaccinated and non-vaccinated individuals infected with Wildtype, Delta, and Omicron SARS-CoV-2. We used multivariable logistic regression models to assess the association and estimate the risk reduction of PCC after infection with newer variants and prior vaccination. We further assessed associations with the severity of PCC using multinomial logistic regression. To identify groups of individuals with similar symptom patterns and evaluate differences in the presentation of PCC across variants, we performed exploratory hierarchical cluster analyses. RESULTS: We found strong evidence that vaccinated individuals infected with Omicron had reduced odds of developing PCC compared to non-vaccinated Wildtype-infected individuals (odds ratio 0.42, 95% confidence interval 0.24–0.68). The odds among non-vaccinated individuals were similar after infection with Delta or Omicron compared to Wildtype SARS-CoV-2. We found no differences in PCC prevalence with respect to the number of received vaccine doses or timing of last vaccination. The prevalence of PCC-related symptoms among vaccinated, Omicron-infected individuals was lower across severity levels. In cluster analyses, we identified four clusters of diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms, with similar patterns across variants. CONCLUSION: The risk of PCC appears to be lowered with infection by the Omicron variant and after prior vaccination. This evidence is crucial to guide future public health measures and vaccination strategies.
format Online
Article
Text
id pubmed-9946205
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-99462052023-02-23 Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts Ballouz, Tala Menges, Dominik Kaufmann, Marco Amati, Rebecca Frei, Anja von Wyl, Viktor Fehr, Jan S. Albanese, Emiliano Puhan, Milo A. PLoS One Research Article BACKGROUND: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. This study aimed to evaluate the prevalence and severity of post COVID-19 condition (PCC) with novel SARS-CoV-2 variants and after prior vaccination. METHODS: We used pooled data from 1350 SARS-CoV-2-infected individuals from two representative population-based cohorts in Switzerland, diagnosed between Aug 5, 2020, and Feb 25, 2022. We descriptively analysed the prevalence and severity of PCC, defined as the presence and frequency of PCC-related symptoms six months after infection, among vaccinated and non-vaccinated individuals infected with Wildtype, Delta, and Omicron SARS-CoV-2. We used multivariable logistic regression models to assess the association and estimate the risk reduction of PCC after infection with newer variants and prior vaccination. We further assessed associations with the severity of PCC using multinomial logistic regression. To identify groups of individuals with similar symptom patterns and evaluate differences in the presentation of PCC across variants, we performed exploratory hierarchical cluster analyses. RESULTS: We found strong evidence that vaccinated individuals infected with Omicron had reduced odds of developing PCC compared to non-vaccinated Wildtype-infected individuals (odds ratio 0.42, 95% confidence interval 0.24–0.68). The odds among non-vaccinated individuals were similar after infection with Delta or Omicron compared to Wildtype SARS-CoV-2. We found no differences in PCC prevalence with respect to the number of received vaccine doses or timing of last vaccination. The prevalence of PCC-related symptoms among vaccinated, Omicron-infected individuals was lower across severity levels. In cluster analyses, we identified four clusters of diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms, with similar patterns across variants. CONCLUSION: The risk of PCC appears to be lowered with infection by the Omicron variant and after prior vaccination. This evidence is crucial to guide future public health measures and vaccination strategies. Public Library of Science 2023-02-22 /pmc/articles/PMC9946205/ /pubmed/36812215 http://dx.doi.org/10.1371/journal.pone.0281429 Text en © 2023 Ballouz et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ballouz, Tala
Menges, Dominik
Kaufmann, Marco
Amati, Rebecca
Frei, Anja
von Wyl, Viktor
Fehr, Jan S.
Albanese, Emiliano
Puhan, Milo A.
Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title_full Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title_fullStr Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title_full_unstemmed Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title_short Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts
title_sort post covid-19 condition after wildtype, delta, and omicron sars-cov-2 infection and prior vaccination: pooled analysis of two population-based cohorts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946205/
https://www.ncbi.nlm.nih.gov/pubmed/36812215
http://dx.doi.org/10.1371/journal.pone.0281429
work_keys_str_mv AT ballouztala postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT mengesdominik postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT kaufmannmarco postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT amatirebecca postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT freianja postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT vonwylviktor postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT fehrjans postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT albaneseemiliano postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts
AT puhanmiloa postcovid19conditionafterwildtypedeltaandomicronsarscov2infectionandpriorvaccinationpooledanalysisoftwopopulationbasedcohorts